Please login to the form below

Zarzio

This page shows the latest Zarzio news and features for those working in and with pharma, biotech and healthcare.

Clock ticking on biosimilar Enbrel in US

In markets outsider the US - where it is known as Zarzio and has been available since 2006 - Sandoz' drug has captured around a 30% share of the Neupogen market.

Latest news

Novartis launches first biosimilar Zarxio in the US

therapies.”. Biosimilars have been available in Europe since 2006 and Zarxio is already available in more than 40 countries under the brand name Zarzio, where it has captured around 30% of
Apotex latest to file Neupogen biosimilar in the US

the brand name Zarzio.
FDA close to first biosimilar approval

US under the brand name Zarzio.
Biosimilars could make EU big cost savings after slow start

In the case of Amgen's once-daily white blood cell stimulator Neupogen (filgrastim), however, the drug has now been overtaken by its biosimilar rivals - led by Sandoz' Zarzio - and the
FDA 'must publish biosimilar naming guide soon'

as Zarzio - in Europe in 2009. ... According to the company Zarzio is the leading G-CSF in Europe with a 30 per cent market share.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Customer experience rules the digital age

Establishing an effective customer journey
Embracing digital disruption in pharma

LEO Innovation Lab and some of its successes to date

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Biosimilars: Getting the flock to market

Biosimilars: Getting the flock to market. The biosimilars field is about to become very crowded. Here are some Life tips on how to stand out from the herd. Biosimilars have now been with us for over 10 years. In case you haven't been paying
Swordfish Advertising

Zarzio. Omnitrope. Adoport. Adoport International. Mezolar Matrix. Pain portfolio. Mometasone. Shire Pharmaceuticals.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

Account Manager – Med Comms – London: Salary TBC

Senior Medical Writer: Great salary and bebefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Account Manager or AD - Medical Communications: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Project Manager, Medical Communications, London: Excellent Salary

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Manager / Account Director: Great salary and bebefits

Senior Medical Writer: Great salary and benefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Scientific Director: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Programme Executive: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Manager – Med Comms – Kent: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Medical Writer, e-learning/ training, London: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Subscribe to our email news alerts

PMHub

Add my company

Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...